UCB SA (UCBJY)
119.58
-0.16
(-0.13%)
USD |
OTCM |
Sep 18, 16:00
UCB Price to Book Value
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 04, 2026 | 7.659 |
| September 03, 2026 | 8.047 |
| September 02, 2026 | 7.992 |
| September 01, 2026 | 7.90 |
| August 31, 2026 | 7.821 |
| August 28, 2026 | 7.842 |
| August 27, 2026 | 8.063 |
| August 26, 2026 | 8.042 |
| August 25, 2026 | 8.189 |
| August 24, 2026 | 8.043 |
| August 21, 2026 | 8.088 |
| August 20, 2026 | 7.893 |
| August 19, 2026 | 8.014 |
| August 18, 2026 | 7.886 |
| August 17, 2026 | 7.787 |
| August 14, 2026 | 7.673 |
| August 13, 2026 | 7.897 |
| August 12, 2026 | 7.998 |
| August 11, 2026 | 8.165 |
| August 10, 2026 | 8.133 |
| August 07, 2026 | 8.085 |
| August 06, 2026 | 8.095 |
| August 05, 2026 | 8.274 |
| August 04, 2026 | 8.052 |
| August 03, 2026 | 7.974 |
| Date | Value |
|---|---|
| July 31, 2026 | 8.044 |
| July 30, 2026 | 7.815 |
| July 29, 2026 | 8.943 |
| July 28, 2026 | 8.911 |
| July 27, 2026 | 8.736 |
| July 24, 2026 | 8.700 |
| July 23, 2026 | 8.639 |
| July 22, 2026 | 8.704 |
| July 21, 2026 | 8.709 |
| July 20, 2026 | 8.446 |
| July 17, 2026 | 8.553 |
| July 16, 2026 | 8.478 |
| July 15, 2026 | 8.474 |
| July 14, 2026 | 8.285 |
| July 13, 2026 | 8.393 |
| July 10, 2026 | 8.506 |
| July 09, 2026 | 8.934 |
| July 08, 2026 | 8.943 |
| July 07, 2026 | 9.052 |
| July 06, 2026 | 9.159 |
| July 02, 2026 | 9.477 |
| July 01, 2026 | 9.195 |
| June 30, 2026 | 9.380 |
| June 29, 2026 | 9.482 |
| June 26, 2026 | 9.194 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Eli Lilly & Co. | 32.04 |
| AstraZeneca PLC | 10.88 |
| Corcept Therapeutics, Inc. | 16.86 |
| Jazz Pharmaceuticals Plc | 3.249 |
| Novo Nordisk A/S | 5.648 |
Price to Book Value Related Metrics
| PE Ratio | 18.14 |
| PS Ratio | 4.668 |
| PEG Ratio | 0.0203 |
| Price to Free Cash Flow | 32.97 |
| Price | 119.58 |
| Earnings Yield | 5.51% |
| Market Cap | 45.60B |
| PEGY Ratio | 0.0203 |
| Operating PE Ratio | 14.67 |
| Normalized PE Ratio | 17.98 |